The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Piper Sandler on January 20, 2026. The analyst firm set a price target for $4.00 expecting IPSC to rise to within 12 months (a possible 54.54% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Piper Sandler, and Century Therapeutics maintained their overweight rating.

There is no last upgrade for Century Therapeutics

The last downgrade for Century Therapeutics Inc happened on November 17, 2025 when Leerink Partners changed their price target from $7 to $2 for Century Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on January 20, 2026 so you should expect the next rating to be made available sometime around January 20, 2027.

While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a maintained with a price target of $2.00 to $4.00. The current price Century Therapeutics (IPSC) is trading at is $2.59, which is within the analyst’s predicted range.